Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy

2000409 citationsJournal Article

Authors

Elinor Ben‐Menachem · Sahlgrenska University Hospital

Abstract

Conversion to LEV monotherapy (1500 mg twice daily) is effective and well tolerated in patients with refractory partial seizures who responded to 3000 mg/d LEV as add-on therapy.

Topics & Keywords

Epilepsy research and treatment Pharmacological Effects and Toxicity Studies Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Epilepsia

Volume 41, Issue 10, pp. 1276-1283

DOI: 10.1111/j.1528-1157.2000.tb04605.x

Field-Weighted Citation Impact: 17.09